Bicycle Therapeutics Presents EphA2 Bicyclic Peptide PET Imaging Data at AACR 2026
Bicycle Therapeutics presented first clinical experiences of a phage-display-derived EphA2-specific bicyclic peptide PET imaging agent in the Diagnostic Biomarkers 2 session at AACR. The imaging agent complements Bicycle's EphA2-targeted therapeutic pipeline (including nuzefatide pevedotin) and could enable patient selection for EphA2-targeted bicyclic peptide drug conjugates across multiple tumor types.